Skip to main content
SpringerLink
Log in

Nateglinide reduces postprandial glucose levels, with a low risk of hypoglycaemia in patients with type 2 diabetes mellitus

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329(14): 977–86

    Article  Google Scholar 

  2. U.K. Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep 12; 352(9131): 854–65

    Article  Google Scholar 

  3. Carswell CI, Culy CR, Perry CM. Management of type 2 diabetes mellitus: defining the role of nateglinide. Dis Manage Health Outcomes 2002; 10(6): 363–83

    Article  CAS  Google Scholar 

  4. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999 Aug 21; 354(9179): 617–21

    Article  Google Scholar 

  5. Landgraf R. Approaches to the management of postprandial hyperglycaemia. Exp Clin Endocrinol Diabetes 1999; 107 Suppl. 4: S128–32

    Article  PubMed  CAS  Google Scholar 

  6. Novartis Pharmaceuticals Corporation. Starlix prescribing information. New Jersey, US: Novartis Pharmaceuticals Corporation, 2000 Dec

  7. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23(11): 1660–5

    Article  PubMed  CAS  Google Scholar 

  8. Holmes D, Raccah D, Escobar-Jimenez F. Targeting postprandial hyperglycaemia in patients with type 2 diabetes: nateglinide vs acarbose [plus poster]. Diabetologia 2001; 44 Suppl. 1: 215

    Google Scholar 

  9. Royal College of General Practitioners Effective Clinical Practice Unit. Clinical guidelines for type 2 diabetes; blood glucose management [online]. Available from URL: http://www.shef.ac.uk/guidelines [Accessed 2002 Mar 9]

  10. British National Formulary. No. 44. London: The Pharmaceutical Press, 2002 Sep

  11. Marre M, Van Gaal L, Usadel K-H, et al. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab. 2000 May; 4(3): 177–86

    Article  Google Scholar 

  12. European Medicines Evaluation Agency. Scientific discussion: Starlix (Nateglinide) [online]. Available from URL: http://www.eudra.org/humandocs/humans/epar/starlix/starlix.htm [Accessed 2002 Apr 6]

  13. Kalbag JB, Walter YH, Nedelman JR, et al. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care 2001 Jan; 24(1): 73–7

    Article  PubMed  CAS  Google Scholar 

  14. Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001 Jun; 24(6): 983–8

    Article  PubMed  CAS  Google Scholar 

  15. Keilson L, Mather S, Walter YH, et al. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000 Mar; 85(3): 1081–6

    Article  PubMed  CAS  Google Scholar 

  16. Landgraf R, Frank M, Bauer C, et al. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int J Obes 2000; 24 Suppl. 3: S38–44

    Article  Google Scholar 

  17. Ishii T, Yamakita T, Yamagami K, et al. Nateglinide is safe and efficacious in lowering postprandial blood glucose in type 2 diabetic patients with various degree of renal function. Diabetes 2001; 50 Suppl. 2: A118

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nateglinide reduces postprandial glucose levels, with a low risk of hypoglycaemia in patients with type 2 diabetes mellitus. Drugs Ther. Perspect 19, 1–4 (2003). https://doi.org/10.2165/00042310-200319050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319050-00001

Keywords

Search

Navigation